News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BLGO BioLargo Validates Key Performance Metrics of Its Cellinity Battery Energy Storage Technology
https://www.accesswire.com/930981/biolargo-validates-key-performance-metrics-of-its-cellinity-battery-energy-storage-technology
WESTMINSTER, CA / ACCESSWIRE / October 14, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary BioLargo Energy Technologies, Inc. completed preliminary internal testing of its prototype battery cells confirming many of the technology's exceptional performance claims that make it an attractive battery technology for long duration energy storage.
The tests, done to verify the battery's performance claims made by its original inventors, confirmed the stability of the chemistry of the battery cell and the reliability of the component construction as a sealed, non-venting cell design with no self-discharging. The tests also helped verify the battery's ability to quickly charge and discharge at a high voltage.
Cellinity™ is BioLargo's next-generation battery platform designed to provide a better alternative to lithium-ion technology for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is safer, more sustainable, longer lasting, and more energy-dense than lithium-ion batteries, traits that make it ideal for large-format long-duration energy storage applications. Learn more about Cellinity at www.BioLargoEnergy.com.
In addition to these internal tests, the company is also organizing third-party validation testing to be done on the more complex aspects of Cellinity's electrochemical performance with at least two acclaimed testing facilities.
Dennis P. Calvert, President and CEO of BioLargo, commented "With these results in hand, our engineers are now advancing the next steps in Cellinity's development: design and production of the larger format 'Spartan' Cellinity cells, and design and production of battery modules containing those cells. Stay tuned - we're very excited about the future of this important battery technology, and we think you should be too."
He continued, "According to a recently published article in The Economist titled 'Clean energy's next trillion-dollar business', global energy storage experts have predicted the global supply of battery energy storage will need to increase from today's 200 gigawatts to more than a terawatt by 2030 and more than five terawatts by 2050, fueling a market projected to be worth between $200 billion and $700 billion by 2030 and between $1 and $3 trillion by 2040. These projections underscore the critical role of batteries in the global energy transition and the massive global investment in battery innovation required to meet those targets. Because of its unique differentiators in safety, energy density, and lifespan, Cellinity is especially well-suited to assist in the global energy transition, and we intend to capitalize on that."
$BLGO BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract
https://www.accesswire.com/879444/biolargo-engineering-increases-ongoing-revenue-with-another-air-force-contract
USAF work now amounts to over $100,000 in revenue per month.
WESTMINSTER, CA / ACCESSWIRE / June 20, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a subcontract to provide air quality services to two Arizona U.S. Air Force bases for up to four years, with expected annual revenue of approximately $812,000.
The news comes on the heels of a similar recently announced contract award to serve three Air Force bases in New Mexico, which has a potential annual average revenue of $650,000. BioLargo's work at the Arizona bases consists primarily of the air quality regulatory compliance portion of a Fence-to-Fence (F2F) support contract through prime contractor HLTLI Joint Venture, LLC, a joint venture between HL Environmental Services and TLI Solutions.
The four-year prime contract secures pricing for F2F services over the term of the contract but does not guarantee continuation of the contract over that duration. In the past, BioLargo's engineers have continued providing services through the duration of the prime contract. In total, BioLargo Engineering's work at Air Force bases now amounts to over $100,000 of revenue per month.
BioLargo Engineering, Science & Technologies President Randall Moore commented, "We are pleased and honored to continue providing vital engineering services to the United States Air Force and supporting their active mission and environmental compliance needs. These new contracts will provide for over $100,000 a month of ongoing fixed revenues while we continue to expand our abilities to support new opportunities."
$BLGO BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products
https://www.accesswire.com/876410/biolargo-subsidiary-clyra-medical-selects-keystone-industries-to-support-manufacturing-of-its-medical-products
WESTMINSTER, CA / ACCESSWIRE / June 12, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. ("Clyra") has selected Keystone Industries, a global manufacturer of medical, dental and cosmetic products with distribution partners in more than 70 countries, to support manufacturing of its medical products. The relationship focuses on the build-out of scaled manufacturing capacity for Clyra's FDA 510(k) cleared Bioclynse surgical wound irrigation solution. Clyra and Keystone have been and continue to make significant investments to support the launch of Bioclynse.
Bioclynse is Clyra's FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:
Non-cytotoxic, non-sensitizing, no damage to tissue
No rinse-out required
Non-staining
Sustained multi-day efficacy
Effective against biofilms
Cary Robinson, President and CEO of Keystone Industries, said, "We are excited to support Clyra Medical Technologies to bring Bioclynse to the market. Keystone has a century of experience in developing and manufacturing medical device, OTC and pharmaceutical products. We have committed a significant investment in our infrastructure to support the manufacturing of innovative products like Clyra's Bioclynse and can readily provide the needed support to scale up production rapidly."
Steve Harrison, President of Clyra Medical Technologies, commented, "We are continuing to work hard and spend money to support the scaled roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing partner willing to invest significant money in new equipment and dedicated space was critical to these efforts. We look forward to a long and mutually prosperous relationship with Keystone."
Looking Great! $BLGO
Nice volume into the close and #HOD $BLGO
$BLGO EPA Adds PFAS to CERCLA (Superfund) Law, Favoring Low-Waste Systems like BioLargo's AEC
https://www.accesswire.com/855647/epa-adds-pfas-to-cercla-superfund-law-favoring-low-waste-systems-like-biolargos-aec
BioLargo’s PFAS treatment technology generates a fraction of the waste compared to carbon filtration
WESTMINSTER, CA / ACCESSWIRE / April 23, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today provided commentary on the importance of a final decision by the U.S. Environmental Protection Agency (EPA) to regulate two per- and polyfluoroalkyl substance (PFAS) chemicals as "hazardous substances" under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as the Superfund law. BioLargo's PFAS treatment solution, the Aqueous Electrostatic Concentrator, generates a small fraction of the volume of PFAS-laden waste that carbon filtration systems generate, thus reducing operational costs of waste handling, transport, and disposal.
In the EPA press release, EPA Administrator Michael S. Regan stated, "Designating these chemicals under our Superfund authority will allow EPA to address more contaminated sites, take earlier action, and expedite cleanups, all while ensuring polluters pay for the costs to clean up pollution threatening the health of communities." These new regulations come on the heels of the EPA's announcement two weeks ago setting PFAS drinking water limits as low as four parts per trillion.
This new EPA action also means that these PFAS chemicals will be listed as "hazardous materials" under the Hazardous Materials Transportation Act, which will require materials containing these chemicals to be transported using special protocols.
Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc., which markets BioLargo's PFAS treatment systems, commented, "We believe these and other upcoming regulations create a price advantage for our AEC system over competing sorbent technologies such as carbon filtration. With less waste generated, we can also offer clients waste handling all the way through to full destruction at our facility."
These finalized CERCLA regulations are the most recent step by the EPA to limit exposure of Americans to PFAS. In addition to the recently announced federal drinking water standards for six PFAS chemicals, the agency also committed $9 billion in funding to help communities and water providers address contamination by PFAS and other emerging contaminants. This funding will assist communities and water providers to acquire PFAS monitoring and treatment systems to comply with new regulations.
Dennis P. Calvert, President and CEO of BioLargo, commented, "We're pleased to see the U.S. government taking PFAS seriously and dedicating the billions of dollars in funding needed to protect municipal water supplies across the country."
hey got a first contract for PFAS
Look at it on: cleantech innovator Biolargo first there you can read: First PFAS REMOVAL CLIENT8
yes it is doubfulll. But going from the third semester , we receive 7.9 million and that is 107% higher than the semester before; i am in for the end of 2023 we go to 10million and perhaps more. I am waiting for the Aec when it receive the pro they need.
Revenue increase a lot and that is necessary! Because there are to much who blame the company in the past.
No way with such results! they have for the first quarter 3.742.000 revenues against revenues last year were 1.544.000 that's more than 288% against last year? Wich company can give you this numbers????. Be in a hurry to buy now. The price is not what it means. This company will show you this year what it can do!!
Joe speaking on yahoo : Finally we know the real value of our shares, and at Monday we will hear more! 0.40$ is in the picture. Im also happy wiith the stories of Pooph! It is a way to invest
Thank you all for the support
The company have the money and now they can go higher , finally! You can invest here!
|
Followers
|
43
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
886
|
|
Created
|
05/07/07
|
Type
|
Free
|
| Moderators | |||
AI
